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Abstract
Background: The 2009 swine-origin influenza virus (S-OIV) H1N1 pandemic has caused more than 18,000 deaths worldwide.
Vaccines against the 2009 A/H1N1 influenza virus are useful for preventing infection and controlling the pandemic. The
kinetics of the immune response following vaccination with the 2009 A/H1N1 influenza vaccine need further investigation.
Methodology/Principal Findings: 58 volunteers were vaccinated with a 2009 A/H1N1 pandemic influenza monovalent
split-virus vaccine (15 mg, single-dose). The sera were collected before Day 0 (pre-vaccination) and on Days 3, 5, 10, 14, 21,
30, 45 and 60 post vaccination. Specific antibody responses induced by the vaccination were analyzed using
hemagglutination inhibition (HI) assay and enzyme-linked immunosorbent assay (ELISA). After administration of the 2009
A/H1N1 influenza vaccine, specific and protective antibody response with a major subtype of IgG was sufficiently developed
as early as Day 10 (seroprotection rate: 93%). This specific antibody response could maintain for at least 60 days without
significant reduction. Antibody response induced by the 2009 A/H1N1 influenza vaccine could not render protection against
seasonal H1N1 influenza (seroconversion rate: 3% on Day 21). However, volunteers with higher pre-existing seasonal
influenza antibody levels (pre-vaccination HI titer $1:40, Group 1) more easily developed a strong antibody protection
effect against the 2009 A/H1N1 influenza vaccine as compared with those showing lower pre-existing seasonal influenza
antibody levels (pre-vaccination HI titer ,1:40, Group 2). The titer of the specific antibody against the 2009 A/H1N1
influenza was much higher in Group 1 (geometric mean titer: 146 on Day 21) than that in Group 2 (geometric mean titer: 70
on Day 21).
Conclusions/Significance: Recipients could gain sufficient protection as early as 10 days after vaccine administration. The
protection could last at least 60 days. Individuals with a stronger pre-existing seasonal influenza antibody response may
have a relatively higher potential for developing a stronger humoral immune response after vaccination with the 2009 A/
H1N1 pandemic influenza vaccine.
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Introduction
From April 2009, a novel influenza virus strain emerged and
quickly spread from the United States and Mexico to the rest of
the world[1]. This 2009 A/H1N1 pandemic caused more than
18,000 deaths worldwide[2]. Great attention and effort were
applied to conquer this pandemic[3]. Recently the WHO declared
our entry into the post-pandemic period and expected the H1N1
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e14270pandemic virus to take on the behavior of a seasonal influenza
virus, which may continue to circulate for some years to come[4].
This 2009 A/H1N1 influenza virus is of swine origin and its
unique genome is a combination of both American and Eurasian
lineages[5,6]. The antigenicity of the virus is distinct from that of
the seasonal human H1N1 influenza A virus and people, especially
young people, generally lack immune protection against this new
virus[5,6].
Several clinical trials have revealed that the split-virus vaccine
against the 2009 A/H1N1 virus, either with or without adjuvant, is
very effective and can establish sufficient protection in the general
population[7,8,9,10]. From these studies, we have determined that
14 or 21 days after vaccine administration, the volunteers
generally develop protection against the 2009 A/H1N1 influenza
virus. However, our knowledge regarding the dynamic, changing
profile of the antibody response at different time points after
vaccine administration is still limited. Here we conducted a single-
dose administration of a non-adjuvanted 2009 A/H1N1 influenza
monovalent split-virus vaccine in a group of 58 volunteers and
studied the specific antibody response before and at days 3, 5, 10,
14, 21, 30, 45 and 60 after vaccine administration. We found that
at as early as day 10, most of the volunteers developed a protective
antibody response (mainly IgG) against the 2009 A/H1N1
influenza virus. This specific response can last at least 60 days
without significant reduction.
Another important question that draws much attention is
whether the pre-existing seasonal influenza antibody response
plays a role during the 2009 A/H1N1 influenza vaccine
administration. Some studies have suggested that the recent
seasonal influenza vaccine administration is unlikely to provide
protection against the 2009 A/H1N1 pandemic influenza
infection[11,12]. In this study, we observed that people with a
higher seasonal H1N1 influenza antibody background more easily
develop a stronger antibody response against the 2009 A/H1N1
influenza after vaccine administration. Similar to this human study
observation, an animal experiment also showed that mice pre-
immunized with seasonal influenza vaccine yielded a slightly
higher GMT after the 2009 A/H1N1 influenza vaccination.
These results indicate that the pre-existing immune status with
respect to the seasonal influenza could be an indicator for assessing
the immune response against the 2009 A/H1N1 pandemic
influenza after vaccination.
Methods
Ethics and Subjects
This study was approved by the Institutional Review Board of
Institut Pasteur of Shanghai, CAS. Healthy non-pregnant adults
between the ages of 18 and 60 were eligible for enrollment.
Subjects who experienced the pandemic 2009 A/H1N1 influenza
infection or vaccine administration were excluded by carefully
reviewing the influenza related clinical records or history. All the
subjects were from Xinxiang, Henan province of China. Written
informed consent that indicated the volunteers’ complete under-
standing of the experimental procedure was obtained from all
subjects. Fifty eight subjects including 46 men and 12 women were
recruited for the study. The ages of the volunteers ranged from 19
to 53 with an average age of 28 and median of 26.
Mice used in this study were handled in strict accordance with
the Guidelines for Animal Care and Use of the Institut Pasteur of
Shanghai, Chinese Academy of Sciences. The protocol was
approved by the Institutional Committee for Animal Experiments
of the Institut Pasteur of Shanghai, CAS. All surgery was
performed under ether anesthesia. All efforts were made to
minimize suffering.
Vaccine
The monovalent 2009 A/H1N1 influenza split-virus vaccine
without adjuvant was produced by Hualan Biological Bacterin
Company, China. It was prepared from reassortant strain X-179A
(by New York Medical College), was derived from the A/
California/7/2009 (H1N1) virus and was recommended by the
World Health Organization. It has been demonstrated effective
and safe for use[8,9]. In this study, we also used another seasonal
H1N1 influenza vaccine for hemagglutination inhibition (HI)
assay. It was prepared from reassortant strain IVR-148 and with
HA gene from the A/Brisbane/59/2007 (H1N1) strain. This
seasonal influenza virus vaccine was also produced by Hualan
Biological Bacterin Company.
Study procedures
The trial lasted from October to December, 2009. The subjects
received one dose of 15 mg split-virus vaccine against the 2009 A/
H1N1 influenza virus on day 0. Serum samples were collected
from all subjects before vaccination and after vaccination on day 3,
day 5, day 10, day 14, day 21, day 30, day 45 and day 60. The
serum samples collected before day 30 were complete and on days
30, 45 and 60 at least 51 samples were collected for each time
point for analysis. The influence of variation of the sample number
was considered and excluded in statistical analysis with the
software used.
Laboratory assays
Antibody titers of all serum samples were determined by means
of hemagglutination inhibition (HI) assay according to established
procedures and with chicken erythrocytes[8]. Briefly, serum
samples were treated with receptor-destroying enzyme (RDE,
cholera filtrate) at 37uC for 18 hours, and then heated at 56uC for
30 minutes. In our HI assay, serum samples were diluted from
1:10 to 1:5120 and we recorded as the HI titer the highest dilution
rate that caused complete hemagglutination inhibition against 4
hemagglutinating units (HAU) of virus. Every serum sample was
assayed in two independent HI tests against the formaldehyde
inactivated 2009 A/H1N1 influenza virus (X-179A reassortant
strain) and the seasonal H1N1 influenza virus (IVR-148
reassortant strain). All tests were repeated at least twice for
recheck of the authenticity of the data.
An enzyme-linked immunosorbent assay (ELISA) was also
performed briefly as the following procedure. Ninety-six-well
micro-titer plates (Nunc) were coated with insect cell expressed
hemagglutinin (HA) protein in 0.1 M carbonate buffer (pH 9.6) at
a concentration of 10 mg/ml at 4uC overnight. Blocking buffer and
dilution buffer consisted of phosphate buffered saline (PBS)
containing 10% bovine serum and 0.1% Tween-20. After blocking
of the plates at 37uC for 2 hours, the plates were washed and 1:50
diluted sera added, then incubated at 37uC for 2 hours. After
washing to remove non-specific binding antibodies, horse radish
peroxidase conjugated goat anti-human IgG or IgM antibody
(Sigma) was diluted and added to the plates which were incubated
at 37uC for another hour. Tetramethylbenzidine (TMB) was used
as the substrate and the absorbance was measured at 450 nm with
a micro-plate autoreader (Thermo).
Mice Vaccination
Six-week-old female BALB/c mice were purchased from
Shanghai Laboratory Animal Center, Chinese Academy of
Pandemic A/H1N1 Vaccine
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Mice were divided into two groups: Group A and Group B (each
group, n=10). On day 0, mice in Group A were vaccinated with
PBS (control) and those in Group B were vaccinated with the
2008-09 trivalent seasonal influenza vaccine. Twenty one days
after the first vaccination (on day 21), both groups were vaccinated
with the 2009 A/H1N1 influenza monovalent split-virus vaccine.
Sera were collected on day 0, 21 and 35. On each time point, the
serum HI titers against both the pandemic and the seasonal
influenza vaccines were determined by the hemagglutination
inhibition assay as described above.
Both of the 2009 A/H1N1 influenza monovalent split-virus
vaccine and the 2008-09 trivalent seasonal influenza vaccine were
produced by Hualan Biological Bacterin Company, China. 6 mg
seasonal influenza vaccine or 7.5 mg 2009 A/H1N1 pandemic
influenza vaccine (in 150 ml sterile PBS, pH 7.4) per mouse was
injected from the quadriceps muscles of both legs using a 29-gauge
needle (BD) with each leg receiving half of the vaccine
administrated. Mouse blood was collected using the retro-orbital
bleeding method and sera were obtained by centrifugation
(10,000 g, 10 min) to remove the blood clot after incubation at
37uC for 2 hours and then at 4uC overnight.
Statistical methods
In this study, the immunogenicity endpoints were seroprotection
rate, seroconversion rate and geometric mean titer (GMT)
according to the international guidelines established by the
European Committee for Medicinal Products to evaluate influenza
vaccines[13]. Based on the criteria established for seasonal
influenza, seroprotection was defined as an HI titer of 1:40 or
more. Seroconversion was defined as an increase of the HI titer by
a factor of four or more with the postvaccination HI titer more
than 1:40. HI titer below 1:10 was assigned a value of 1:5 in
calculating the GMT.
The Student’s t-test and the Pearson’s chi-squared test were
used to compare different groups of data. P values of 0.05 or less
were considered significant. All statistical data were calculated
using R software (version 2.10.1).
Results
Dynamics of antibody response to 2009 A/H1N1 vaccine
in human volunteers
Serum levels of antibody against hemagglutinin were deter-
mined using a hemagglutination inhibition assay, which is a
standard assay used in the process of licensing influenza vaccines.
Seroprotection rate, seroconversion rate and geometric mean titer
are calculated for the HI assay to express the sero-response after
influenza virus infection or vaccination. Table 1 shows that before
vaccination the seroprotection rate and GMT against 2009 A/
H1N1 virus were kept at a baseline, 12% and 16 respectively.
After vaccination, they increased gradually. On day 5, seroprotec-
tion rate, seroconversion rate and GMT achieved 47%, 19% and
32 respectively. On day 10, seroprotection rate, seroconversion
rate and GMT achieved 93%, 72% and 86, which levels are
almost sufficient to protect subjects against the 2009 A/H1N1
virus infection. The explosive growth of the antibody titer
occurred between day 5 and day 10 (p=7.0e-10). A reasonable
explanation is that specific IgG antibodies against HA began to be
generated at this stage (Figure 1). On day 14, seroprotection rate,
seroconversion rate and GMT achieved 97%, 86%, and 112
respectively. The antibody titer almost reached its maximum on
day 14 and remained nearly unchanged from day 14 to day 60.
We concluded that the 2009 A/H1N1 influenza vaccine was
effective in establishing protection on day 10 after vaccination and
that this protection could be maintained for at least 60 days.
Compared with the baseline, seroprotection rate, seroconversion
rate and GMT on day 5 and thereafter all showed very big
statistical differences with the p values generally less than 0.001
(except the seroconversion rate on day 5). The pattern of the HA-
specific IgG antibody response determined by ELISA was almost
in accordance with the HI assay results (Figure 1). The specific
IgM response against HA is very low and did not show significant
differences among different time points in our ELISA experiments
(data not shown). There was no cross reactivity of the IgG and
IgM ELISAs under the working dilution rates of the goat anti-
human IgG or IgM enzyme conjugated antibody, a finding that
Table 1. Dynamic Changes of the Hemagglutination-Inhibition Titers against the 2009 A/H1N1 Virus after Administration of the
2009 A/H1N1 Influenza Vaccine.
Time Seroprotection rate -% (95% CI) Seroconversion rate - % (95% CI) GMT (95% CI)
Pre (N=58) 12 (5-23) - 16 (13-20)
day 3 (N=58) 19 (10-31) 5 (1-14) 19 (15-24)
day 5 (N=58) 47 (33-60)** 19 (10-31)* 32 (27-38)**
day 10 (N=58) 93 (83-98)** 72 (59-83)** 86 (68-108)**
day 14 (N=58) 97 (88-100)** 86 (75-94)** 112 (88-142)**
day 21 (N=58) 97 (88-100)** 86 (75-94)** 113 (89-144)**
day 30 (N=51) 98 (90-100)** 88 (76-96)** 117 (92-149)**
day 45 (N=55) 95 (85-99)** 84 (71-92)** 117 (91-150)**
day 60 (N=56) 95 (85-99)** 84 (72-92)** 113 (88-145)**
Seroprotection is defined as HI titer of 1:40 or more. Seroconversion is defined as postvaccination HI titer of 1:40 or more, increasing at least four times. GMT=geometric
mean titer. HI titers below 1:10 were assigned a value of 1:5, in calculating the geometric mean titer.
*(p,0.05) and
**(p,0.001) represent the statistical significances compared with the pre-vaccination values (day 3 value for seroconversion rate). The Pearson’s chi-squared test was
used for the seroprotection and seroconversion rate analysis, the two-way Student’s t-test for the GMT analysis. Pre: pre-vaccination.
doi:10.1371/journal.pone.0014270.t001
Pandemic A/H1N1 Vaccine
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protein for detection (data not shown). A dilution rate of 1:200 or
less of the sera could show a positive result in the ELISA and 1:50
was chosen to obtain an appropriate OD value.
We also analyzed the dynamic changes of the antibody response
against seasonal H1N1 virus after vaccination with the 2009 A/
H1N1 influenza vaccine (Table 2). Before vaccination, the
seroprotection rate and GMT against seasonal H1N1 virus were
59% and 30 respectively. On day 21, the seroprotection rate and
GMT were 64% and 37, which barely increased as compared with
the baseline (p=0.70). Obviously, the 2009 A/H1N1 influenza
vaccine showed no cross protection against the seasonal H1N1
influenza virus. Similar results were also obtained from HI
experiments concerning a 2008-09 trivalent seasonal influenza
vaccine (data not shown).
Pre-existing antibody to seasonal influenza is predictive
of a higher antibody response to the 2009 A/H1N1
vaccine
To investigate the relationship of the antibody response of the
seasonal influenza and the 2009 A/H1N1 influenza, the 58
subjects were further divided into two groups based upon their
baseline HI titers against the 2008-09 seasonal trivalent influenza
vaccine. Group 1 contained 38 subjects whose baseline HI titers
against seasonal influenza vaccine were $1:40. Group 2 contained
20 subjects whose seasonal influenza HI titers were less than 1:40.
The seroprotection rate, seroconversion rate and GMT for the
2009 A/H1N1 influenza vaccine in Group 1 and Group 2 were
calculated at each time point until day 21 post vaccination
(Table 3). There was no statistical difference between Group 1 and
Group 2 with regard to seroprotection rate and seroconversion
rate (p=1.0 on day 21, data not shown). However, Group 1
achieved a relatively higher GMT (146 on day 21 after
vaccination), in contrast to Group 2 which generated a relatively
lower one (70 on day 21). Group 1 showed markedly higher
antibody titers than Group 2 at each time point after vaccination
(p,0.05), especially on day 10, 14 and day 21 (p,0.001).
Mouse correlate of Table 3
To further confirm the observation in Table 3, a mouse
experiment was conducted. On day 0, two groups (10 in each) of
six-week-old SPF BALB/c mice were vaccinated with PBS (Group
A) or the seasonal influenza vaccine (Group B) respectively.
Twenty one days post vaccination (on day 21), both groups were
further vaccinated with the 2009 A/H1N1 influenza vaccine. Sera
were collected on day 0, 21 and 35. The GMT against the
seasonal and the 2009 A/H1N1 influenza vaccine were deter-
mined and compared with each other. As shown in Table 4, the
significant higher HI titers against the seasonal influenza vaccine
on day 21 and 35 in Group B as compared to Group A (p,0.001)
demonstrated a successful seasonal influenza vaccination. The
strong antibody response against the 2009 A/H1N1 influenza
vaccine on day 35 in both groups indicated an effective
administration of the 2009 A/H1N1 influenza vaccine. Impor-
tantly, the GMT against the 2009 A/H1N1 influenza vaccine on
day 35 of Group B was slightly higher than that of Group A (197
to 149). Although the difference is not statistical significant
(p=0.17), the result is in accordance with the observation of the
human study (Table 3). This result suggests that the pre-existing
immune response background of the seasonal influenza may be
helpful for generating a stronger antibody response against the
2009 A/H1N1 influenza vaccine.
Discussion
Influenza A viruses cause epidemics every year and occasionally
global pandemics due to their highly variable genome. Seasonal
influenza vaccines are revised every 1–3 years to cope with
mutations in the HA and NA proteins of circulating viruses[14].
However, the mechanism by which a new pandemic influenza
virus appears and the strategy applied by the virus to escape
Table 2. Dynamic Changes of the Hemagglutination-Inhibition Titers against the Seasonal H1N1 Virus after Administration of the
2009 A/H1N1 Influenza Vaccine.
Time Seroprotection rate -% (95% CI) Seroconversion rate - % (95% CI) GMT (95% CI)
Pre (N=58) 59 (45-71) - 30 (24-38)
day 3 (N=58) 59 (45-71) 3 (0-12) 32 (25-40)
day 5 (N=58) 59 (45-71) 3 (0-12) 32 (25-41)
day 10 (N=58) 60 (47-73) 3 (0-12) 36 (29-46)
day 14 (N=58) 64 (50-76) 3 (0-12) 38 (30-47)
day 21 (N=58) 64 (50-76) 3 (0-12) 37 (30-46)
doi:10.1371/journal.pone.0014270.t002
Figure 1. ELISA to detect specific anti-HA IgG antibody at
different time points in the sera of volunteers for the 2009 A/
H1N1 influenza vaccine administration. The OD450 nm on
different days were measured and results were displayed as
DOD450 nm with each prevaccination (baseline) OD subtracted in
every subject’s serial samples. "pre": pre-vaccination. The OD value of
the pre-vaccination sera was 0.7660.06 (IgG baseline). The blank OD
(no sera added) of the ELISA was 0.05. **: p,0.001, two-way Student’s
t-test.
doi:10.1371/journal.pone.0014270.g001
Pandemic A/H1N1 Vaccine
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the best way to prevent influenza virus infection.
To determine the antibody’s dynamic, changing profile
following the 2009 A/H1N1 influenza vaccine administration is
a very important task. It could allow prediction of the point at
which the influenza vaccine takes effect and how long the effect
will last. Our work demonstrates that most vaccine recipients
obtain protection as early as 10 days after vaccination and that
protection is maintained for at least 60 days. This protection is
likely due to the anti-HA IgG subtype antibodies.
Importantly, we observed that people with a better seasonal
influenza antibody response more easily reached a higher
protective antibody level after the 2009 A/H1N1 influenza
vaccine administration. This may be due to the fact that some
people may have a good immune response and in spite of seasonal
influenza or the 2009 A/H1N1 pandemic influenza they
encounter, a generally more intensive antibody response could
be induced among them. In addition, other viral infections may
also contribute to the low antibody response against the seasonal
influenza. Another explanation is that the pre-existing seasonal
influenza immune response provides some priming effect for the
2009 A/H1N1 influenza vaccine administration. We noticed that
Del Giudice et al. carried out experiments in ferrets and
demonstrated that seasonal influenza vaccination could provide
a priming effect to the 2009 A/H1N1 influenza vaccine[15].
Garcia-Garcia et al. also demonstrated clinically that seasonal
trivalent influenza vaccine could partially protect people from the
2009 A/H1N1 influenza infection[16]. As indicated by these
reports, the stronger antibody response in the higher seasonal
influenza antibody level group, as we observed, might also be due
to the priming effect of the pre-existing seasonal influenza immune
response, an assumption also supported by the observation that
serum IgG against HA increased dramatically between day 5 and
day 10 after vaccination (Figure 1).
The result of the mice experiment is similar to that of the
human study though not dramatic, which might be due to the
small animal number. It indicates that the priming effect of the
pre-existing seasonal influenza immune response may have some
promoting role on the pandemic influenza vaccination. However,
in the human study, we cannot neglect the influence of the
subject’s immune system on generating immune response against
the vaccine. Both of the priming effect and the immune system
status could be important factors influencing the protection result
in human vaccination.
The reason for using 1:40 as the criterion to define Group 1 and
Group 2 in Table 3 is that this titer is considered seroprotective by
a number of authorities[13,17]. Work published in 1984 showed
that a titer of 1:42 for H1N1 and 1:44 for H3N2 provided 50%
protection against infection[18].
Our study suggests that to obtain an optimal effect for the 2009
A/H1N1 influenza vaccination, one should consider the
recipient’s previous seasonal influenza antibody level. It is a
potential indicator for predicting whether a good vaccination
effect can be achieved. Our resu l t ss u g g e s tt h a tm u l t i p l e
Table 3. Geometric Mean HI Titers against the 2009 A/H1N1 Influenza Virus in Two Groups of People with Different Seasonal
Influenza Antibody Levels.
Seroprotective for seasonal influenza prior to vaccination?
Time Yes{ (N=38) (95% CI) No u (N=20) (95% CI)
Pre (N=58) 18 (14-24)* 12 (9-16)
day 3 (N=58) 23 (17-31)* 14 (11-18)
day 5 (N=58) 37 (29-48)* 25 (21-29)
day 10 (N=58) 111 (82-150)** 53 (40-69)
day 14 (N=58) 143 (104-198)** 70 (54-89)
day 21 (N=58) 146 (105-203)** 70 (54-89)
{Individuals with prevaccination seasonal influenza HI titer $1:40.
u Individuals with prevaccination seasonal influenza HI titer ,1:40.
*(p,0.05) and
**(p,0.001) represent the statistical differences between the two groups, two-way Student’s t-test.
doi:10.1371/journal.pone.0014270.t003
Table 4. Geometric Mean HI Titer against the Seasonal and the 2009 A/H1N1 Influenza Virus in Two Groups of Mice with Different
Vaccination Procedures
#.
Day 0 Day 21 Day 35
GMT (95% CI) Seasonal 2009 A/H1N1 Seasonal 2009 A/H1N1 Seasonal 2009 A/H1N1
Group A (N=10) 5 (5-5) 5 (5-5) 5 (5-5) 5 (5-5) 5 (5-5) 149 (104-215)
Group B (N=10) 5 (5-5) 5 (5-5) 160 (115-223)** 5 (5-5) 160 (115-223)** 197 (155-250)
#Group A: mice immunized with PBS (control) on day 0 and the 2009 A/H1N1 influenza vaccine on day 21; Group B: mice immunized with the 2008-09 trivalent seasonal
influenza vaccine on day 0 and the 2009 A/H1N1 influenza vaccine on day 21.
Seasonal: geometric mean HI titer against the 2008-09 trivalent seasonal influenza vaccine; 2009 A/H1N1: geometric mean HI titer against the 2009 A/H1N1 pandemic
influenza vaccine.
**(p,0.001) represents the statistical differences between Group A and Group B (two-way Student’s t-test).
doi:10.1371/journal.pone.0014270.t004
Pandemic A/H1N1 Vaccine
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influenza antibody levels.
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